title: Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
abstract: In this prospective study, we examined the effect of atorvastatin treatment on baroreflex sensitivity (BRS) in subjects with type 2 diabetes. A total of 79 patients with type 2 diabetes with dyslipidaemia were recruited. A total of 46 subjects were enrolled to atorvastatin 10 mg daily and low-fat diet and 33 patients to low-fat diet only. BRS was assessed non-invasively using the sequence method at baseline, 3, 6 and 12 months. Treatment with atorvastatin increased BRS after 12 months (from 6.46 ± 2.79 ms/mmHg to 8.05 ± 4.28 ms/mmHg, p = 0.03), while no effect was seen with low-fat diet. Further sub-analysis according to obesity status showed that BRS increased significantly only in the non-obese group (p = 0.036). A low dose of atorvastatin increased BRS in non-obese subjects with type 2 diabetes and dyslipidaemia after 1-year treatment. This finding emphasizes the beneficial effect of atorvastatin on cardiovascular system, beyond the lipid-lowering effects.
authors.affiliation: First Department of Propaedeutic and Internal Medicine, Athens University Medical School, Laiko General Hospital, Athens, Greece.
authors.forename: Pinelopi
authors.initials: P
authors.lastname: Grigoropoulou
authors.forename: Ioanna
authors.initials: I
authors.lastname: Eleftheriadou
authors.forename: Christos
authors.initials: C
authors.lastname: Zoupas
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Makrilakis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Papassotiriou
authors.forename: Alexandra
authors.initials: A
authors.lastname: Margeli
authors.forename: Despoina
authors.initials: D
authors.lastname: Perrea
authors.forename: Nicholas
authors.initials: N
authors.lastname: Katsilambros
authors.forename: Nicholas
authors.initials: N
authors.lastname: Tentolouris
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D017704:Baroreflex / Q000187:drug effects*; D015992:Body Mass Index; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D058065:Diabetic Cardiomyopathies / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018752:Diet, Fat-Restricted; D050171:Dyslipidemias / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006115:Greece / Q000453:epidemiology; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D063806:Myalgia / Q000139:chemically induced; D009765:Obesity / Q000150:complications; D010352:Patient Dropouts; D011446:Prospective Studies; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D002317:Cardiovascular Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin
keywords: Atorvastatin; autonomic function; baroreflex sensitivity; diabetes